澳大利亚批准黑色素瘤疗法Amtagvi，Iovance上涨

2026-06-05 00:27

Shares of Iovance Biotherapeutics (IOVA) climbed on Thursday after the Therapeutic Goods Administration of Australia granted conditional approval for the company’s cell therapy, Amtagvi, as a late-line option for the skin cancer, melanoma.
The first FDA-approved T cell therapy for a solid tumor indication, Amtagvi, will therefore be available in Australia for adults with previously treated unresectable or metastatic melanoma, the San Carlos, California-based biotech said in a statement on Wednesday.
The company also announced plans to receive authorization for its first Amtagvi treatment center in Australia, the country with the highest prevalence of melanoma in the world, with 17,000 new patients diagnosed annually.
“This approval in Australia is our third marketing authorization for Amtagvi and marks a significant step forward for Iovance in the country with the highest rate of melanoma globally,” added interim CEO Frederick Vogt.

More on Iovance Biotherapeutics